

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascletois Pharma Inc.
歌禮製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1672)

VOLUNTARY ANNOUNCEMENT

**GANOVO® ENROLLED IN THE BASIC MEDICAL INSURANCE OF
TIANJIN — CAPPED REIMBURSEMENT-PER-
PATIENT PILOT PROGRAM**

The board of directors of Ascletois Pharma Inc. (the “**Company**”) is pleased to announce that Ganovo® (Danoprevir) has been enrolled in the Basic Medical Insurance of Tianjin — Capped Reimbursement-per-patient Pilot Program for outpatients with hepatitis C.

By Order of the Board of Directors
Ascletois Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People’s Republic of China
September 26, 2018

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; Mr. Wei FU, as non-executive Director; and Dr. Ru Rong JI, Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.